<table>
  <thead>
    <tr>
      <th></th>
      <th>Pipeline</th>
      <th>SHC Supply</th>
      <th>SHC Strategy</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><strong>Critical Shortages</strong></td>
      <td></td>
      <td></td>
      <td></td>
    </tr>
    <tr>
      <td>Dextrose 50% INJ</td>
      <td>Production delays. Next Release date = mid Q1 2020.</td>
      <td>Limited.</td>
      <td>Therapeutic Countermeasures: Centralize remaining syringes and vials for crash carts. Convert patients over to oral glucose agents. In-house compounding / batching D20 bags.</td>
    </tr>
    <tr>
      <td>Erwinaze</td>
      <td>Intermittent backorder. Full Recovery = TBD.</td>
      <td></td>
      <td>Case by case determinations of use by Oncology Teams.</td>
    </tr>
    <tr>
      <td>Improvue</td>
      <td>Shortage through end of Q3 2019.</td>
      <td></td>
      <td></td>
    </tr>
    <tr>
      <td>Miochol - E</td>
      <td>No forecasted recovery date.</td>
      <td></td>
      <td></td>
    </tr>
    <tr>
      <td><strong>Concern Shortages</strong></td>
      <td></td>
      <td></td>
      <td></td>
    </tr>
    <tr>
      <td>Aggrastat</td>
      <td>Production delays through Q1 2020.</td>
      <td></td>
      <td>SBAR ready to be activated once supply reaches critically low.</td>
    </tr>
    <tr>
      <td>Bupivacaine INJ</td>
      <td>Production delays through end of Q4.</td>
      <td>Limited</td>
      <td>Allocate inventory to PeriOp.</td>
    </tr>
    <tr>
      <td>Cardene Premade Bags</td>
      <td>Production delays through end of Q4 2019.</td>
      <td>Limited</td>
      <td>Therapeutic Countermeasures: Encourage providers to utilize alternatives such as oral antihypertensive or IV clevidine. If SHC runs out of nicardipine or patient cannot tolerate oral therapy and/or IV clevidine, IV sodium nitroprusside can be utilized</td>
    </tr>
    <tr>
      <td>Dopamine IV</td>
      <td>Limitation on production through 2019.</td>
      <td>Limited</td>
      <td>Available: Dopamine 800mg / 250ml bags</td>
    </tr>
    <tr>
      <td>Epinephrine 10ml SYR</td>
      <td>Production delays. No forecasted recovery date.</td>
      <td>none</td>
      <td>Available: 1mg/1ml INJ Pharmacy will begin placing epinephrine emergency syringe KITs in crash cart medication trays as crash carts are refilled.</td>
    </tr>
    <tr>
      <td>Fluorescein Sodium Injection: 25% (2mL)</td>
      <td>Long term backorder status. Severe limitation on production until end of 2019.</td>
      <td>none</td>
      <td>Available: AK-FLUOR 10% VIAL</td>
    </tr>
    <tr>
      <td>IVIG</td>
      <td>Shortage through Q2 2020.</td>
      <td></td>
      <td>ALL IVIG cases require approval per shortage standard procedure.</td>
    </tr>
  </tbody>
</table>

Please contact Deepak Sisodiya @ dsisodiya@stanfordhealthcare.org with any questions.
<table>
<thead>
<tr>
<th>Drug</th>
<th>Status</th>
<th>Criticality</th>
<th>Pharmacist Guidance</th>
</tr>
</thead>
</table>
| Sodium Bicarbonate INJ| Intermittent backorder. Full Recovery = **Early September.** | **50ml vials** | SHC should limit use of sodium bicarbonate to critical indications for which alternatives are not available. 
Approved Indications for Use: 
1. Cardiac arrest 
2. Cardiac surgery & transplant cases 
3. Hydration for high-dose methotrexate 
4. Allogeneic BMT chemo hydration (use low dose bicarb) 
5. Severe Acidosis (pH<7.20) 
For all other indications, pharmacist to page team to recommend alternatives. Do not use for the following indications due to lack of evidence favoring sodium bicarbonate over alternatives. 
1. Prevention of contrast-induced nephropathy 
2. Rhabdomyolysis 
3. Urinary Alkalization 
4. Lidocaine buffering |
| Unasyn INJ            | Manufacturer shortage through Q3 2019.      | Critically LOW | Pharmacists to recommend therapeutic alternatives.                                  |
| Vinblastine INJ       | Manufacturer shortage through mid Q4 2019.  | Critically LOW | Reserving the existing limited inventory for patients who are already on the therapy plan w/ vinblastine. |

Please contact Deepak Sisodiya @ dsisodiya@stanfordhealthcare.org with any questions.